ABL Bio’s Grabody lands record heigh $2.6B deal with Lilly
ABL Bio has signed a major license and research collaboration with Eli Lilly worth up to $2.602 billion, granting access to its Grabody bispecific platform.
Neurology
Groundbreaking Collaboration Between Manifold Bio and Roche Launches $2B-Plus Brain-Shuttle Program
Manifold Bio inks a groundbreaking collaboration with Roche to apply AI-guided brain-shuttle technology for neurological therapies.
HAS Stroke Update Transforms Access on World Stroke Day
HAS strengthens stroke management for faster, equitable emergency care access.
Novartis secures triumphant $12 billion takeover of Avidity
The billion-dollar acquisition advances Avidity’s RNA platform with momentum.
Judge Rules ReWalk Device Is Medically Necessary for Medicare
Medicare exoskeleton coverage approved for ReWalk Personal Exoskeleton, sets key precedent.
Vor Bio and RemeGen Seal $4B Global License Agreement
Vor Bio, RemeGen sign Global License Agreement for RC98 development.
Neuron23’s NEU-411 Trial Shifts the Parkinson’s Paradigm Toward Precision
Neuron23 advances NEU-411 into Phase II Parkinson’s trial, driven by biomarker-based strategies and strong investor support.
TISSIUM’s De Novo FDA Authorization Signals Industry Shift
FDA De Novo nod for TISSIUM’s COAPTIUM CONNECT: a new era in sutureless nerve repair.
Strategic Industry Context: Alzheimer’s Drug Reimbursement Faces Global Pressure
NICE deems donanemab and lecanemab not cost-effective, blocks NHS coverage for Alzheimer’s drugs.